OneVentures Welcome Image

OneVentures is a venture capital firm headquartered in Sydney, Australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies.

The firm is particularly focused on opportunities originating in Australia which are poised to expand into the established and emerging global markets.

All of our Partners have founded, built and exited high-growth businesses.

Our goal is to be the leading Australian venture capital company.

Proudly supporting

Heads Over Heels
Investor Portal Log In

Connect With Us

About OneVentures

OneVentures invests in technology companies that serve or disrupt large high growth global markets. The firm has $170M in funds under management recently launching its new Innovation and Growth Fund II which is focused on growth and expansion stage technology companies.

OneVentures is managed by a team of Partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.

The OneVentures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance.


OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Director and CEO

Dr Paul Kelly

Dr Paul Kelly
Partner and Managing Director

Anne-Marie Birkill

Anne-Marie Birkill
General Partner and Executive Director

Graeme Wald

Graeme Wald
Venture Partner

Daniel Gammell

Daniel Gammell
Investment Manager

Dr Amir Zalcenstein

Dr Amir Zalcenstein
Investment Manager, Healthcare

James McGrath

James McGrath
Investment Analyst

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob

Jen Ball

Jen Ball
Office Manager


Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund formed as an early stage venture capital Limited Partnership. This Fund was launched in 2010 with the Commonwealth Government committing $20M from its IIF programme and this funding matched by high net-worth wholesale investors.

Innovation and Growth Fund (Fund II)

The OneVentures Innovation and Growth Fund was launched in March 2014 with a target of $100M and reached that target in December 2015. Fund II is an early stage venture capital limited partnership backed entirely by Australian high net-worth wholesale investors.

Focusing on later stage (Series B and beyond) investments while still maintaining some investment activity in the earlier stage investments, Fund II is now screening investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success.

We are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our Application for Funding page and submit your application now.

Information for stakeholders interested in the Significant Investment Visa (SIV) Programme

Information for stakeholders interested in the Significant Investment Visa Programme can be found here.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

OneVentures Innovation and Growth Fund (Fund II)

Other Investments

Latest News

  • Media Release - OneVentures appoints Dr Graeme Wald to life sciences investment team

    by WE Buchan | Sep 01, 2016
    31 August 2016

    OneVentures, a venture capital fund focused on investment in high growth and transformative technology and life sciences companies, is pleased to announce the appointment of Dr Graeme Wald as a Venture Partner.

    OneVentures, which has $170 million of funds under management, invests in technology and life sciences companies providing human and investment capital, and plays an active role in leadership and fund raising for its portfolio companies. Its most notable achievement in life sciences is its investment in Hatchtech. OneVentures currently owns nearly 40% of the company and has led financing rounds that raised over $24 million over the past six years.  Representing Hatchtech’s largest shareholder and acting as Chairman of the company, OneVentures’ Paul Kelly played a leading role in securing a $279 million licencing deal with Dr Reddy’s for the company’s lead product, egg lice treatment Xeglyze™. The transaction could return up to $100 million to OneVentures’ investors.

    Dr Wald, brings more than 20 years of biotechnology, pharmaceutical and healthcare investment and research to OneVentures,  holding senior roles in both the buy and sell side. His most recent position was Investment Director at Bioscience Managers, a specialist life science fund manager.  Graeme has also held equity research roles at Wilson HTM, UBS and Merrill Lynch. In 2007 he was named as the top rated analyst in Australia for pharmaceutical, healthcare and biotechnology, as measured by investment returns and recommendations, by Starmine.

    OneVentures said Graeme's appointment reflects the firm's global focus. Dr Wald, was previously a  Non-Executive Director of NexVet where he assisted in guiding the Company to a listing on NASDAQ.  OneVentures partners between them have previously led 4 Nasdaq listed companies as either founder/co-founder and/or CEO with combined market values of over $1B and have led numerous M&A transactions in US and Europe.  OneVentures continues to build out its strength and leverage its international networks in driving Australian innovation and companies through to significant value in global markets.

    Managing Partner of OneVentures, and head of the LifeSciences team, Dr Paul Kelly said, “We are very pleased to welcome an investment professional with Graeme’s experience to the LifeSciences and Healthcare team. His academic background, experience in capital markets, and work with a wide range of healthcare and biotechnology companies aligns with our vision to add value to our investments by helping to foster growth and nurture companies along the commercialisation journey.

    “We’re seeing a definite increase in venture capital investment in the Australian market; innovation is firmly on the government agenda, and new investment funds such as the Biotechnology Translation Fund will be integral in attracting new interest in early stage technologies. We’re very committed to building our team, and presence in this area, to continue to translate great Australian research and innovation, into commercial products addressing global market needs.”


    For more information, contact:

    Paul Kelly
    Tel: +61 2 8205 7379

    Kyahn Williamson
    WE Buchan
    Tel: +61 40 101 8828

    About OneVentures:

    OneVentures is a Sydney-based venture capital firm with $170M under management that invests in emerging Australian companies with differentiated products particularly in the information technology and life sciences sectors that address large and growing global markets.  OneVentures is managed by a team of partners with a track record of hands-on business execution and operational management: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong technical and scientific pedigree, extensive off-shore experience and networks combined with investment management expertise.  This skill-set makes the team ideally suited to supporting and mentoring entrepreneurial management to help them drive growth and create value in their companies and subsequently, through leveraging collective experience, reduce portfolio company risk and enhance portfolio returns for OneVentures’ investors.

    OneVentures Innovation Fund I and OneVentures Innovation and Growth Fund II are formed as Early Stage Venture Capital Limited Partnerships (ESVCLPs). ESVCLP returns are tax free on income and capital account for national and international investors. The OneVentures Innovation Fund I is a $40 million venture capital fund raised in 2010 and is supported by the Australian Government through the IIF (Innovation Investment Fund) program with this funding matched by institutional investors, individual high net worth investors and family offices. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.  

    OneVentures Fund II is a $100M later stage venture growth fund focusing on technology rich companies.  The Fund is particularly interested in companies developing products in the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security.

    Read more about OneVentures at


Full story

Contact Us

For Entrepreneurs

We are now screening companies for OneVentures Fund II which is a Series A and beyond growth fund focusing on the technology sector. To qualify for funding, your company should meet the following criteria:

  • Australian domiciled company
  • We invest in technology companies from many sectors, but we are particularly interested in companies from the following sectors: healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, software, sensors and robotics or food security
  • If a life sciences company, your product should have a strong proof of concept and be at a minimum, in a late stage clinical trial and/or well progressed through the regulatory process
  • If from another sector, your company should be generating sustainable revenue and have a strong market validation
  • Approaching profitability with capital required to fuel growth and global expansion

If you meet the above criteria, send us a brief document (a 2-page executive summary or introductory PowerPoint is sufficient, please do not send larger documents or full information memorandums at this stage) covering at a minimum the following points to

  • Summarize in 2 sentences what your company does (this is important)
  • Identify the market, value proposition and your competitive advantage
  • Tell us about your progress to date
  • State your revenue for the last financial year and projected revenue for current financial year
  • Indicate capital required and how it will be used
  • Include 3 point bios of each executive and contact details

We will review your proposal and endeavour to revert to you within 2 weeks. 


For Investors

Investor enquiries:

Information for stakeholders interested in the Significant Investment Visa (SIV) Programme

The Significant Investor Visa (SIV) programme was revised with the announcement in May 2015 of a new complying investment framework. The new framework mandated that SIV applicants would be required to invest a minimum of $500,000 at the at time of investment in an AusIndustry registered fund(s): that is, a VCLP, ESVCLP or an Australian VC fund-of-fund as registered under the Venture Capital Act 2002. The minimum amount is expected to be increased within two years as the market responds.

The Austrade website has more information regarding the programme available, including information sheets in English and Chinese.

The relevant regulations can be accessed here.

OneVentures is not at this time accepting new capital commitments and is therefore not in a position to receive funding from individual SIV applicants. When this situation changes we will provide details here and on the AVCAL website.

We are however receiving proposals from SIV Fund of Funds interested in becoming a OneVentures SIV partner for 2016 and beyond. If you represent a Fund of Funds and meet the following criteria we request you submit a brief proposal for our consideration.

Our criteria:

  • You should have a track record in servicing SIV applicants
  • You should have an established Australian AML/CTF KYC compliance framework that OneVentures can rely on in accepting SIV funding
  • You should be an AusIndustry compliant fund of funds structure – OneVentures will not accept direct investment from individual SIV applicants at this stage
  • You should have a fund of funds structure that can invest the capital for up to 10 years in line with our funding cycle

Your proposal should address those key criteria and provide information about:

  • The Directors
  • The Management Team
  • Your track record in providing SIV applicants with a return on investment
  • How you will ensure AML/CTF KYC compliance including details of any external providers that support this process
  • Details of any relevant reporting and financial operational requirements we should consider
  • Your ability to source capital and the % of SIV market you currently hold/expected quantum of capital you would be looking to deploy p.a. to VC

We plan to work with up to 3 such partners only and will determine the parties with whom we wish to progress discussions by December 2015.


General Enquiries

General enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Suite 304, Level 3
1 Alfred Street
Sydney NSW 2000


c/- Interfinancial
Level 3, 145 Eagle Street
Brisbane QLD 4000


For Media Enquiries

For an interview with a OneVentures' spokesperson, please contact Honner Media at +61 2 8248 3744.